Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147. Issue 5 (9th May 2016)

• Record Type: Journal Article
• Authors: Phipps, Amanda I.; Shi, Qian; Limburg, Paul J.; Nelson, Garth D.; Sargent, Daniel J.; Sinicrope, Frank A.; Chan, Emily; Gill, Sharlene; Goldberg, Richard M.; Kahlenberg, Morton; Nair, Suresh; Shields, Anthony F.; Newcomb, Polly A.; Alberts, Steven R.
• Is Part Of: International journal of cancer. Volume 139:Issue 5(2016:Sep. 01)
• Page Start: 986
• Page End: 995
• Publication Date: 2016-05-09
• Subjects: colon cancer -- alcohol -- survival -- recurrence -- red wine; Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.30135
• Languages: English
• ISSNs: 0020-7136

Abstract

Abstract : Alcohol consumption is associated with a modest increased risk of colon cancer, but its relationship with colon cancer survival has not been elucidated. Using data from a phase III randomized adjuvant trial, we assessed the association of alcohol consumption with colon cancer outcomes. Patients completed a risk factor questionnaire before randomization to FOLFOX or FOLFOX + cetuximab ( N = 1984). Information was collected on lifestyle factors, including smoking, physical activity and consumption of different types of alcohol. Cox models assessed the association between alcohol consumption and outcomes of disease‐free survival (DFS), time‐to‐recurrence (TTR) and overall survival (OS), adjusting for age, sex, study arm, body mass, smoking, physical activity and performance status. No statistically significant difference in outcomes between ever and never drinkers were noted [hazard ratio (HR)DFS = 0.86, HRTTR = 0.87, HROS = 0.86, p ‐values = 0.11–0.17]. However, when considering alcohol type, ever consumers of red wine ( n = 628) had significantly better outcomes than never consumers (HRDFS = 0.80, HRTTR = 0.81, HROS = 0.78, p ‐values = 0.01–0.02). Favorable outcomes were confirmed in patients who consumed 1‐30 glasses/month of red wine ( n = 601, HR = 0.80–0.83, p ‐values = 0.03–0.049); there was a suggestion of more favorable outcomes in patients who consumed >30 glasses/month of red wine ( n = 27, HR = 0.33–0.38, p ‐values = 0.05–0.06). Beer and liquor consumption were not associated with outcomes. Although alcohol consumption was not associated with colon cancer outcomes overall, mild to moderate red wine consumption was suggestively associated with longer OS, DFS and TTR in stage III colon cancer patients. Abstract : What's New? Drinking red wine may boost the odds of surviving colon cancer, according to a new analysis. In this paper, the authors investigated how alcohol consumption affects colorectal cancer outcomes. Previous work showed that moderate to heavy drinking put an individual at increased risk; this study went further, analyzing the effect of different drinks separately. While they found no association between alcohol consumption and outcomes overall, when they looked only at red wine, they found that people who drank between 1–30 glasses of red wine per month had better outcomes than those who did not drink wine.